Skip to content

FARS Trial

Exploratory study on the safety and efficacy of oral finerenone for renal function impairment after renal surgery

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1031250666
Enrollment
10
Registered
2026-01-23
Start date
2026-04-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients who have undergone kidney-related surgery Diabetic patients who have undergone kidney-related surgery

Interventions

Administration of finerenone for 6 months to diabetic patients after kidney surgery.
finerenone

Sponsors

Kakutani Shigenori
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who have undergone kidney surgery (2) Patients with diabetes mellitus who have an HbA1c >= 6.5% or are being treated with antidiabetic medication within 1 year prior to obtaining consent. (3) Patients with Chronic Kidney Disease (CKD). (4) Age: 18 years or older and less than 85 years at the time of obtaining consent. (5) Sex: Any. (6) Patients who have given written informed consent of their own free will after receiving a full explanation regarding participation in this study and fully understanding the contents. (7) Patients who are able to visit the outpatient clinic according to the study schedule

Exclusion criteria

Exclusion criteria: (1) Patients requiring treatment with anticancer drugs or similar agents. (2) Patients with active renal or systemic inflammation. (3) Patients with an eGFR 4.8 mEq/L at the time of enrollment. (7) Patients with severe hepatic impairment (Child-Pugh Class C). (8) Patients with Addison's disease. (9) Patients who are pregnant or possibly pregnant. (10) Patients who are breastfeeding. (11) Any other patients deemed ineligible for participation in this study by the Principal Investigator or Co-Investigator

Design outcomes

Primary

MeasureTime frame
Incidence of adverse events for which a causal relationship with the investigational drug cannot be ruled out

Secondary

MeasureTime frame
(1) Degree of improvement in renal function at 24 weeks after administration. (2) Degree of improvement in proteinuria at 24 weeks after administration. (3) Renal ultrasonography assessment at 24 weeks after administration. (4) Incidence of all adverse events

Contacts

Public ContactShigenori Kakutani

The University of Tokyo Hospital

kakushigean@yahoo.co.jp+81-3-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026